Tilmann Brotz

Tilmann is a senior Development Sciences Consultant with over 15 years of experience in the biopharmaceutical industry leading toxicology, DMPK, in-vivo pharmacology, clinical pharmacology and diagnostic groups. Most recently Dr. Brotz was Sr. Director, Development Sciences at Achaogen where he contributed to multiple antibiotics programs from lead optimization through Phase 3. Prior to Achaogen, Dr. Brotz worked as head of preclinical development and as a consultant for numerous emerging companies, including VIA Pharmaceuticals where he led the non-clinical and clinical efficacy for a clinical Phase 2 5lipoxygenase inhibitor. He is an advisor for the CLSI FAST Program and a member of the Scientific Review Board of the Alzheimer’s Drug Discovery Foundation.